Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study

Background: Postmenopausal osteoporosis is a multifactorial disease. Genetic factors play an essential role in contributing to bone mineral density (BMD) variability, which ranges from 60 to 85%. Alendronate is used as the first line of pharmacological treatment for osteoporosis; however, some patie...

Full description

Bibliographic Details
Main Authors:	Alejandra Villagómez Vega, Jorge Iván Gámez Nava, Francisco Ruiz González, Misael Pérez Romero, Walter Ángel Trujillo Rangel, Ismael Nuño Arana
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Genes
Subjects:	osteoporosis alendronate bone mineral density single nucleotide polymorphism osteogenic profile personalized therapy
Online Access:	https://www.mdpi.com/2073-4425/14/2/524

Similar Items

Two Years of Alendronate and Calcitonin Treatments for Osteoporosis in Postmenopausal Women - Original Investigation
by: Gülcan Gürer, et al.
Published: (2006-03-01)

The Effect of Alendronate in Male Osteoporosis
by: Özlem El, et al.
Published: (2004-12-01)

The Comparison of Effects of Alendronate and Raloxifene Treatment in Postmenopausal Women with Osteoporosis - Original Investigation
by: Gülcan Gürer, et al.
Published: (2006-03-01)

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004-03-01)

Use of alendronate in the therapy of osteoporosis
by: O. B. Ershova
Published: (2020-01-01)

Enhanced osteogenic differentiation of alendronate-conjugated nanodiamonds for potential osteoporosis treatment
by: Guk Young Ahn, et al.
Published: (2021-09-01)

Comparison of Effectiveness of Strontium Ranelate and Alendronate Sodium in Postmenopausal Osteoporosis - Original Investigation
by: Kurtuluş Kaya, et al.
Published: (2009-12-01)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
by: Asma Radwan, et al.
Published: (2022-04-01)

Effect of Vitamin K and Alendronate Combination Treatment on Bone Mineral Density of Postmenopausal Osteoporosis Patients: A Pilot Study
by: Mohammad Hassan Jokar, et al.
Published: (2016-01-01)

The Comparison of Effects of Alendronate and Calcitonin Treatment in Men With Osteoporosis
by: Gülcan Gürer, et al.
Published: (2004-09-01)

Efficacy of generic alendronate and ibandronate in post menopausal osteoporosis
by: NP Somasundaram, et al.
Published: (2012-03-01)

The comparison of effects of alendronate and raloxifene treatment in postmenauposal women with osteoporosis - Original Investigation
by: Gülcan Gürer, et al.
Published: (2005-12-01)

Effects of Alendronate, Calcitonin and Raloxifene Used in the Treatment of Postmenopausal Osteoporosis On Serum No Levels
by: Saliha Karatay, et al.
Published: (2005-03-01)

PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass
by: Zhao J, et al.
Published: (2021-12-01)

An academic clinical study to assess the efficacy and safety of nandrolone decanoate and alendronate compared with alendronate alone in patients with osteoporosis
by: Bharat R Dave, et al.
Published: (2023-01-01)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
by: Ruxu You, et al.
Published: (2020-11-01)

The Effect of Alendronate Treatment on Bone Density and Bone Markers in Postmenopausal Osteoporosis
by: S. Akı, et al.
Published: (2002-03-01)

Bone-targeted polymeric nanoparticles as alendronate carriers for potential osteoporosis treatment
by: Chunlan Jing, et al.
Published: (2022-06-01)

Effect of Weekly Alendronate on Knee Symptoms in Patients with Osteoporosis and Knee Osteoarthritis Coexistence - Original Investigation
by: Levent Ediz, et al.
Published: (2010-04-01)

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis
by: Antonino Catalano, et al.
Published: (2021-05-01)

The Effect of Alendronate and Calcitonin Treatments on Bone Mineral Density and Quality of Life in Women With Postmenopausal Osteoporosis
by: F. Taşçıoğlu, et al.
Published: (2002-06-01)

The Effects of Once-Weekly Alendronate 70 mg, Risedronate 35 mg and Raloxifene 60 mg Daily in the Treatment of Postmenopausal Osteoporosis in Turkish Population
by: Mesut Öktem, et al.
Published: (2007-04-01)

The Effect of Alendronate and Intranasal Calcitonin Treatments on Bone Mineral Density in Men with Idiopathic Osteoporosis
by: F. Taşçıoğlu, et al.
Published: (2003-03-01)

Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis
by: Elma Kučukalić-Selimović, et al.
Published: (2011-02-01)

Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment
by: Jarusriwanna A, et al.
Published: (2024-02-01)

Irrational use of alendronate sodium by the elderly
by: Camila Pereira Alvim, et al.
Published: (2020-11-01)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
by: Fatemeh Khanizadeh, et al.

Comparison of the effect of alendronate and pamidronate on bone density of patients with osteoporosis
by: Zohre Nobakht, et al.
Published: (2018-12-01)

Modern principles for the diagnosis and treatment of postmenopausal osteoporosis: a focus on bisphosphonates
by: I. B. Belyaeva, et al.
Published: (2020-08-01)

Alendronate-Induced Osteonecrosis of the Jaw in an Elderly Female
by: Bi-Wei Jan, et al.
Published: (2012-06-01)

The Impact of Alendronate on Bone Mineral Density of Osteoporotic Patients
by: Hamidreza Aghaei-Meybodi, et al.
Published: (2013-12-01)

Short term sodium alendronate administration improves the peri-implant bone quality in osteoporotic animals
by: Danila de OLIVEIRA, et al.

Atypical femoral fracture in the setting of alendronate treatment for osteoporosis: a case report and literature review
by: Eric D. Van Baarsel, et al.
Published: (2019-07-01)

Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
by: Fatemeh Shirani, et al.
Published: (2015-10-01)

Evaluation of Alendronate Efficacy on Bone Mineral Density in Thalassemic Patients
by: Fatemeh Shirani, et al.
Published: (2012-10-01)

Circular RNA atlas in osteoclast differentiation with and without alendronate treatment
by: Jianbiao Lin, et al.
Published: (2020-07-01)

Cost–effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain
by: Enrique Casado, et al.
Published: (2023-09-01)

Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
by: José L. Calvo-Gallego, et al.
Published: (2022-08-01)

Effects of Alendronate and Raloxifene on Bone Density and Bone Turnover Markers in Postmenopausal Women
by: Ebru Zülfikaroğlu, et al.
Published: (2011-04-01)

The Efficacy of Alendronate Treatment in Ambulatory Stroke Patients
by: Nihal ÖZARAS, et al.
Published: (2016-04-01)